NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis $0.22 +0.03 (+15.56%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.19▼$0.2550-Day Range$0.16▼$0.6452-Week Range$0.14▼$69.00Volume14.16 million shsAverage Volume3.86 million shsMarket Capitalization$3.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Allarity Therapeutics alerts: Email Address Allarity Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.60) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.56 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Allarity Therapeutics.Read more about Allarity Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.20% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently decreased by 67.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLR. Previous Next 2.3 News and Social Media Coverage News SentimentAllarity Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Allarity Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows4 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.08% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allarity Therapeutics are expected to grow in the coming year, from ($2.60) to ($1.56) per share.Read more about Allarity Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Allarity Therapeutics Stock (NASDAQ:ALLR)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More ALLR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLR Stock News HeadlinesJuly 26 at 7:21 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allarity Therapeutics, Inc. - ALLRJuly 26 at 4:00 PM | globenewswire.comAllarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 26 at 9:00 AM | globenewswire.comAllarity Therapeutics Announces Postponement of Annual Stockholders MeetingJuly 26 at 5:40 AM | americanbankingnews.comAllarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest UpdateJuly 25 at 7:36 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLRJuly 25 at 4:18 PM | tmcnet.comALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJuly 24 at 12:30 PM | investorplace.comALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse SplitJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 11:39 AM | globenewswire.comInvestigation Into Allarity Therapeutics, Inc. (ALLR) Announced by Holzer & Holzer, LLCJuly 24 at 6:00 AM | globenewswire.comAllarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesJuly 23, 2024 | tmcnet.comThe Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of InvestorsJuly 23, 2024 | bizjournals.comBoston biotech says SEC may take ‘enforcement action’ against itJuly 23, 2024 | benzinga.comAllarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer ProgramJuly 22, 2024 | finance.yahoo.comAllarity Therapeutics Outlines Company’s 2024 Progress and ObjectivesJuly 22, 2024 | globenewswire.comAllarity Therapeutics Outlines Company's 2024 Progress and ObjectivesJuly 22, 2024 | globenewswire.comAllarity Therapeutics Outlines Company's 2024 Progress and ObjectivesMay 20, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementSee More Headlines Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-96.94% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.62) per share Price / Book-0.01Miscellaneous Outstanding Shares17,607,000Free Float17,593,000Market Cap$3.92 million OptionableNot Optionable Beta0.28 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Thomas H. Jensen (Age 46)Founder, CEO, Senior VP of Investor Relations & Director Ms. Joan Y. Brown (Age 70)Chief Financial Officer Comp: $180kMr. Peter Buhl Jensen Adj Professor (Age 69)M.D., M.D., Ph.D., Ph.D., Co-Founder Comp: $546.08kDr. Steen Meier Knudsen Ph.D. (Age 63)Founder & Chief Scientific Officer Comp: $185.11kKey CompetitorsVaccinexNASDAQ:VCNXTraws PharmaNASDAQ:TRAWMonopar TherapeuticsNASDAQ:MNPREterna TherapeuticsNASDAQ:ERNANeuroSense TherapeuticsNASDAQ:NRSNView All Competitors ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed this year? Allarity Therapeutics' stock was trading at $11.0220 at the beginning of 2024. Since then, ALLR shares have decreased by 98.0% and is now trading at $0.2228. View the best growth stocks for 2024 here. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($22.14) EPS for the quarter. When did Allarity Therapeutics' stock split? Allarity Therapeutics shares reverse split on Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
